Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.65 |
| ▸ | LPL | P06858 | 12/20 | 0.65 |
| ▸ | SNCA | P37840 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464505 | 0.94 | CA1 (0.59) | LIPGLPLSNCACA1CA2 | |
| SCHEMBL25658494 | 0.89 | CA1 (0.54) | LIPGLPLSNCACA1CA2 | |
| SCHEMBL4757371 | 0.88 | LIPG (0.50) | LIPGLPLSNCACA1CA2 | |
| SCHEMBL16382782 | 0.87 | LIPG (0.50) | LIPGLPLSNCACA1CA2 | |
| SCHEMBL24608995 | 0.86 | LIPG (0.83) | LIPGLPLSNCACA1CA2 | |
| SCHEMBL2707320 | 0.86 | LIPG (0.83) | LIPGLPLSNCACA1CA2 | |
| SCHEMBL10281532 | 0.84 | CA1 (0.50) | LIPGLPLSNCACA1CA2 | |
| SCHEMBL15220523 | 0.84 | CA1 (0.50) | LIPGLPLSNCACA1CA2 | |
| Pentane SCHEMBL23632864 | 0.84 | LPL (0.59) | LIPGLPLSNCACA1CA2 | |
| SCHEMBL15481240 | 0.84 | P4HB (0.50) | LIPGLPLSNCACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193058-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC | 2022-06-23 | — | — | US | disclosed |
| CN-114206843-A | Compounds for modulating proprotein convertase subtilisin/Kexin type 9(PCSK9) | SRX心脏有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2020252383-A2 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193058-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | LIPG 9/4885LPL 6/4885SNCA 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.